A retrospective evaluation of the epithelial changes/lesions and neoplasms of the gallbladder in turkey and a review of the existing sampling methods: a multicentre study

Autor: Ayhan S, Özgür Ekinci, Akarca Fg, Karabacak T, Burcu Saka, Şükrü Oğuz Özdamar, Bostan T, Karslıoğlu Y, Zuhal Gucin, Nuray Kepil, Burak Bahadir, Ipek Erbarut Seven, Bulut T, Gülen Akyol, Banu Ozguven Yilmaz, Samir Abdullazade, Esra Erden, Sevinc Hallac Keser, Sevinc Celik, Fatma Markoç, Selma Sengiz Erhan, Cigdem Ataizi Celikel, Anil Aysal Agalar, Günal A, Çelik B, Işık E, Berna Savaş, Kaymaz E, Nesrin Turhan, Serdar Balci, Guldal Esendagli, Deniz Tuncel, Özgün G, Nurullah Zengin, Ozgul Sagol, Asuman Argon

Publikováno v: Türk Patoloji Dergisi, Vol 34, Iss 1, Pp 41-48 (2018)

Objective: As there is continuing disagreement among the observers on the differential diagnosis between the epithelial changes/lesions and neoplasms of the gallbladder, this multicentre study was planned in order to assess the rate of the epithelial

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::000b4f45ee22debc035ea7d8ac5a2c37
https://doi.org/10.5146/tjpath.2017.01404

Abnormal TP53 Predicts Risk of Progression in Patients With Barrett's Esophagus Regardless of a Diagnosis of Dysplasia.

Autor: Redston M; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address: mredston@partners.org., Noffsinger A; Inform Diagnostics, Irving, Texas., Kim A; Department of Molecular Oncology, Dana Farber Cancer Institute, Boston, Massachusetts., Akarca FG; Department of Molecular Oncology, Dana Farber Cancer Institute, Boston, Massachusetts., Rara M; Department of Pathology, University of California San Francisco, San Francisco, California., Stapleton D; Inform Diagnostics, Irving, Texas., Nowden L; Inform Diagnostics, Irving, Texas., Lash R; R Lash MD, LLC, Southlake, Texas., Bass AJ; Department of Molecular Oncology, Dana Farber Cancer Institute, Boston, Massachusetts; Eli and Edythe L. Broad Institute, Cambridge, Massachusetts., Stachler MD; Department of Pathology, University of California San Francisco, San Francisco, California. Electronic address: Matthew.Stachler@UCSF.edu.

Publikováno v: Gastroenterology [Gastroenterology] 2022 Feb; Vol. 162 (2), pp. 468-481. Date of Electronic Publication: 2021 Oct 29.

Reprogramming of the esophageal squamous carcinoma epigenome by SOX2 promotes ADAR1 dependence.

Autor: Wu Z; Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Cancer Program, The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA., Zhou J; Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Cancer Program, The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA., Zhang X; Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Cancer Program, The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.; Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Zhang Z; Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Cancer Program, The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA., Xie Y; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Liu JB; Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Ho ZV; Cancer Program, The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA., Panda A; Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Committee on Immunology, The University of Chicago, Chicago, IL, USA., Qiu X; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Cejas P; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Cañadas I; Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA, USA., Akarca FG; Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., McFarland JM; Cancer Program, The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA., Nagaraja AK; Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Cancer Program, The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Goss LB; Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Kesten N; Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Si L; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA., Lim K; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Liu Y; Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Zhang Y; Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Baek JY; Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Liu Y; Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Cancer Program, The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA., Patil DT; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Katz JP; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Hai J; Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Bao C; Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Cancer Program, The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA., Stachler M; Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Qi J; Cancer Biology Department, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Ishizuka JJ; Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Cancer Program, The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA., Nakagawa H; Herbert Irving Comprehensive Cancer Center, Division of Digestive and Liver Diseases, Department of Medicine, Columbia University, New York, NY, USA., Rustgi AK; Herbert Irving Comprehensive Cancer Center, Division of Digestive and Liver Diseases, Department of Medicine, Columbia University, New York, NY, USA., Wong KK; Division of Hematology and Medical Oncology, Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY, USA., Meyerson M; Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Cancer Program, The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA., Barbie DA; Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Cancer Program, The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA., Brown M; Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Long H; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Bass AJ; Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. ab5147@cumc.columbia.edu.; Cancer Program, The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA. ab5147@cumc.columbia.edu.; Herbert Irving Comprehensive Cancer Center, Division of Hematology and Oncology, Department of Medicine, Columbia University, New York, NY, USA. ab5147@cumc.columbia.edu.

Publikováno v: Nature genetics [Nat Genet] 2021 Jun; Vol. 53 (6), pp. 881-894. Date of Electronic Publication: 2021 May 10.

Gain-of-Function RHOA Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric Cancer.

Autor: Zhang H; Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Schaefer A; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Wang Y; Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Hodge RG; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Blake DR; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Diehl JN; Curriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Papageorge AG; Laboratory of Cellular Oncology, NCI, NIH, Bethesda, Maryland., Stachler MD; Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Liao J; Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Zhou J; Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Wu Z; Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Akarca FG; Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., de Klerk LK; Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Derks S; Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Pierobon M; Center for Applied Proteomics and Molecular Medicine, School of Systems Biology, George Mason University, Manassas, Virginia., Hoadley KA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.; Curriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Wang TC; Division of Gastroenterology, Columbia University Medical Center, New York, New York., Church G; Harvard, MIT, Blavatnik Institute, Wyss Institute, Boston, Massachusetts., Wong KK; Division of Hematology and Oncology, New York University, New York, New York., Petricoin EF; Center for Applied Proteomics and Molecular Medicine, School of Systems Biology, George Mason University, Manassas, Virginia., Cox AD; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.; Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Lowy DR; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Der CJ; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. adam_bass@dfci.harvard.edu channing_der@med.unc.edu.; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.; Curriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Bass AJ; Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. adam_bass@dfci.harvard.edu channing_der@med.unc.edu.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.

Publikováno v: Cancer discovery [Cancer Discov] 2020 Feb; Vol. 10 (2), pp. 288-305. Date of Electronic Publication: 2019 Nov 26.

A Retrospective Evaluation of the Epithelial Changes/Lesions and Neoplasms of the Gallbladder in Turkey and a Review of the Existing Sampling Methods: A Multicentre Study.

Autor: Esendağlı G; Department of Medical Pathology, Gazi University School of Medicine, Ankara, Turkey., Akarca FG, Balcı S, Argon A, Erhan SŞ, Turhan N, Zengin Nİ, Keser SH, Çelik B, Bulut T, Abdullazade S, Erden E, Savaş B, Bostan T, Sağol Ö, Ağalar AA, Kepil N, Karslıoğlu Y, Günal A, Markoç F, Saka B, Özgün G, Özdamar ŞO, Bahadır B, Kaymaz E, Işık E, Ayhan S, Tunçel D, Yılmaz BÖ, Çelik S, Karabacak T, Seven İE, Çelikel ÇA, Gücin Z, Ekinci Ö, Akyol G

Publikováno v: Turk patoloji dergisi [Turk Patoloji Derg] 2018; Vol. 34 (1), pp. 41-48.